Main Research Contents:

The aim of this study was to evaluate the therapeutic effects of I3.1 in two experimental models of colitis, a dextran sulfate sodium (DSS)-induced colitis model and an interleukin (IL)-10-deficient mice model.

Main Research Findings:

The bacterial strains in the I3.1 formula have been shown to produce SCFAs from indigestible carbohydrates in vitro, mostly acetate but also butyrate, release soluble polyphosphate granules, and display strong inhibitory activity against enterobacteria. Moreover, at the administered doses, I3.1 was able to significantly induce reparative processes in the gut mucosa and reduce clinical symptoms in the DSS model.

Lorén, et al. 
Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis.
Probiotics Antimicrob Proteins. 2016 Mar;9(1):71-80.